{"Symbol": "IQV", "AssetType": "Common Stock", "Name": "IQVIA Holdings Inc", "Description": "IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.", "CIK": "1478242", "Exchange": "NYSE", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "DIAGNOSTICS & RESEARCH", "Address": "2400 ELLIS ROAD, DURHAM, NC, UNITED STATES, 27703", "OfficialSite": "https://www.iqvia.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "28429883000", "EBITDA": "3431000000", "PERatio": "21.27", "PEGRatio": "0.944", "BookValue": "38.34", "DividendPerShare": "None", "DividendYield": "None", "EPS": "7.85", "RevenuePerShareTTM": "94.88", "ProfitMargin": "0.0834", "OperatingMarginTTM": "0.149", "ReturnOnAssetsTTM": "0.0503", "ReturnOnEquityTTM": "0.214", "RevenueTTM": "16310000000", "GrossProfitTTM": "5430000000", "DilutedEPSTTM": "7.85", "QuarterlyEarningsGrowthYOY": "0.236", "QuarterlyRevenueGrowthYOY": "0.103", "AnalystTargetPrice": "246.1", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "16", "AnalystRatingHold": "5", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "21.27", "ForwardPE": "12.74", "PriceToSalesRatioTTM": "1.743", "PriceToBookRatio": "4.354", "EVToRevenue": "2.583", "EVToEBITDA": "12.16", "Beta": "1.361", "52WeekHigh": "247.05", "52WeekLow": "134.65", "50DayMovingAverage": "222.92", "200DayMovingAverage": "192.59", "SharesOutstanding": "169600000", "SharesFloat": "160932000", "PercentInsiders": "1.061", "PercentInstitutions": "102.996", "DividendDate": "None", "ExDividendDate": "None"}